Meta-analysis of adjuvant chemotherapy on prognosis for gastric cancer patients after D2 dissection.
- Author:
Guang-gai XIA
1
;
Chang-hua ZHANG
;
Zhe-wei WEI
;
Ying WU
;
Yu-long HE
Author Information
- Publication Type:Journal Article
- MeSH: Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gastrectomy; Humans; Male; Neoplasm Recurrence, Local; Prognosis; Randomized Controlled Trials as Topic; Stomach Neoplasms; drug therapy; mortality; surgery; Survival Rate
- From: Chinese Journal of Surgery 2013;51(5):447-451
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate efficacy of adjuvant chemotherapy after D2 dissection on survival for patients with gastric cancer.
METHODSRandomized clinical trials (RCT) that compared adjuvant chemotherapy after D2 dissection with D2 dissection alone for gastric cancer were searched with Pubmed, Cochrane, Embase and CBM databases. Eligible trials published between 1990 and 2012 were included in the study. The quality of RCTs was assessed by the Jadad scale. Data synthesis and statistical analysis were performed by RevMan 5.1 software.
RESULTEight RCTs with 3633 patients were included in this study. Among them, 1824 patients received adjuvant chemotherapy and 1809 patients didn't. Adjuvant chemotherapy was associated with a significant benefit in terms of overall survival (RR = 0.76, 95% CI: 0.69-0.84), disease free survival (RR = 0.72, 95%CI: 0.66-0.80) and recurrence rate (RR = 0.69, 95% CI: 0.62-0.77).
CONCLUSIONAdjuvant chemotherapy was associated with survival benefit for gastric cancer after D2 dissection.
